JHS Svendgaard confirms no encumbrance on promoter shares for FY26

1 min read     Updated on 20 May 2026, 05:32 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

JHS Svendgaard Laboratories Limited disclosed that its promoters and promoter group members did not create any direct or indirect encumbrance on shares during FY26. The confirmation, dated April 01, 2026, was submitted under Regulation 31(4) of SEBI Takeover Regulations and covers four individuals including Mr. Nikhil Nanda.

powered bylight_fuzz_icon
40780804

*this image is generated using AI for illustrative purposes only.

JHS Svendgaard Laboratories Limited has informed the stock exchanges that its promoters and members of the promoter group have not created any encumbrance on their shares during the financial year 2025-2026. This disclosure was submitted in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The company confirmed that neither direct nor indirect encumbrances were established on the respective shares held by the promoters during the specified period. The communication, dated April 01, 2026, was addressed to the Audit Committee of the company, BSE Limited, and the National Stock Exchange of India Limited for their information and records.

Promoter Details

The disclosure covers the following individuals and entities identified as promoters and members of the promoter group as on March 31, 2026:

S. No. Name(s) Category
1. Mr. Nikhil Nanda Promoter
2. Mrs. Sushma Nanda Promoter Group
3. Mr. Daljit Singh Grewal Promoter Group
4. Late Sh. Harish Chander Nanda Promoter Group

The statement was submitted on behalf of all promoters and members of the promoter group by Nikhil Nanda, a Promoter of the company.

Historical Stock Returns for JHS Svendgaard Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-2.11%-3.90%-9.90%-25.20%-40.34%-60.56%

How might the promoters' decision to maintain unencumbered shareholding influence investor confidence and potential institutional interest in JHS Svendgaard Laboratories going forward?

Could the clean encumbrance record strengthen JHS Svendgaard's position if the company seeks to raise capital through debt or equity instruments in the near future?

With Late Sh. Harish Chander Nanda still listed as a promoter group member, how might the eventual transfer or redistribution of his shareholding impact the promoter holding structure and control dynamics?

JHS Svendgaard Laboratories
View Company Insights
View All News
like17
dislike

JHS Svendgaard Laboratories Submits Q4FY26 SEBI Compliance Certificate for Dematerialization

1 min read     Updated on 15 Apr 2026, 01:52 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

JHS Svendgaard Laboratories Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 15, 2026, covering dematerialization activities for the quarter ended March 31, 2026. The company's registrar agents Alankit Assignments Limited and Beetal Financial & Computer Services provided separate confirmations for different periods within the quarter, verifying proper compliance with dematerialization procedures and regulatory requirements.

powered bylight_fuzz_icon
37786928

*this image is generated using AI for illustrative purposes only.

JHS Svendgaard Laboratories Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) to both BSE and NSE for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate on April 15, 2026, through Company Secretary and Compliance Officer Komal Jha.

Regulatory Compliance Framework

The certificate submission fulfills requirements under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide quarterly confirmations regarding the dematerialization process of physical share certificates.

Parameter Details
Filing Date April 15, 2026
Quarter Covered Q4FY26 (January-March 2026)
Regulation SEBI Regulation 74(5)
Filed By Komal Jha, Company Secretary

Registrar Confirmations

Two registrar and transfer agents provided separate confirmations covering different periods within the quarter:

Alankit Assignments Limited issued its certificate on April 14, 2026, covering the period from January 1, 2026 to February 23, 2026. General Manager Kamal Garg confirmed that securities received for dematerialization were properly verified, mutilated, and cancelled, with depository names substituted in company records as registered owners.

Beetal Financial & Computer Services provided confirmation for the period from February 24, 2026 to March 31, 2026. The certificate, dated April 9, 2026, was signed by General Manager Punit Mittal, confirming compliance with dematerialization procedures.

Compliance Verification Process

Both registrars confirmed adherence to standard dematerialization protocols:

  • Securities comprised in certificates are listed on stock exchanges
  • Physical certificates underwent due verification before mutilation and cancellation
  • Depository names were substituted in member registers within prescribed timelines
  • All dematerialization requests were confirmed to depositories as accepted or rejected

Corporate Information

Detail Information
Company Name JHS Svendgaard Laboratories Limited
CIN L74110HP2004PLC027558
Registered Office Trilokpur Road, Kheri (Kala Amb), District Sirmaur, Himachal Pradesh
BSE Scrip Code 532771
NSE Trading Symbol JHS

The filing demonstrates the company's ongoing commitment to regulatory compliance and transparent corporate governance practices. The systematic approach to dematerialization ensures proper maintenance of shareholder records and adherence to SEBI guidelines for depositories and participants.

Historical Stock Returns for JHS Svendgaard Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-2.11%-3.90%-9.90%-25.20%-40.34%-60.56%

What factors led JHS Svendgaard to switch registrar services from Alankit Assignments to Beetal Financial mid-quarter?

How might the company's Q4FY26 financial performance impact its stock liquidity and dematerialization volumes in the upcoming quarter?

Will JHS Svendgaard's compliance track record influence institutional investor interest in the pharmaceutical sector?

JHS Svendgaard Laboratories
View Company Insights
View All News
like16
dislike

More News on JHS Svendgaard Laboratories

1 Year Returns:-40.34%